Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): results of the primary analysis.
Lesniewski-Kmak, K Moiseenko, V Saunders, Mark P Wasan, H Argiles, G Borg, C Creemers, G Fedyanin, M Glynne-Jones, R Pfeiffer, P
Lesniewski-Kmak, K
Moiseenko, V
Saunders, Mark P
Wasan, H
Argiles, G
Borg, C
Creemers, G
Fedyanin, M
Glynne-Jones, R
Pfeiffer, P
Citations
Altmetric:
Abstract
Description
Date
2018-06
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): results of the primary analysis. 2018, 29(Suppl_5): Ann Oncol